|
|
|
|
Trial | Studied trt | Control trt | patients | tags | ROB | Trial result | |
---|
|
JCOG, 2005 | docetaxel | doxorubicin + cyclophosphamide | | 1st line | Exploratory | negative | |
Blohmer, 2010 | docetaxel + epirubicin | epirubicin, cyclophosphamide | | 1st line | Risk of bias | negative | |
Rivera , 2008 | Weekly Docetaxel | Every three weeks Docetaxel | | | | - | |
Tabernero , 2004 | Weekly Docetaxel | Every three weeks Docetaxel | | | | - | |
Sedky , 2002 | Weekly Docetaxel | Every three weeks Docetaxel | | | | - | |
Willemse , 2007 | Weekly Docetaxel | Every three weeks Docetaxel | | | | - | |
Bontenbal, 2005 | docetaxel + doxorubicin | fluorouracil, doxorubicin, cyclophosphamide | | 1st line | Risk of bias | suggesting | |
Bonneterre, 2004 | docetaxel + epirubicin | fluorouracil, epirubicin, cyclophosphamide | | | Risk of bias | suggesting | |
TXT Group, 2002 | docetaxel | fluorouracil, vinorelbine | | 2nd line previous anthracycline | Exploratory | suggesting | |
304 Study Group, 1999 | docetaxel | mitomycin, vinblastine | | 2nd+ line previous anthracycline | Risk of bias | suggesting | |
Sjostrom, 1999 | docetaxel | sequential methotrexate and 5-fluorouracil | | 2nd+ line previous anthracycline | Exploratory | suggesting | |
HERNATA, 2011 | docetaxel + trastuzumab | vinorelbine, trastuzumab | | 1st line HER-2 positive | Exploratory | suggesting | |
|
TAX 317 (Shepherd) 100mg/m2, 2000 | docetaxel | | | | | - | |
TAX 320 100mg/m2, 2000 | docetaxel | | | | | - | |
DISTAl 01 (Gridelli) , 2004 | weekly docetaxel | 3-weekly docetaxel | | | | - | |
Camps | weekly docetaxel | 3-weekly docetaxel | | | | - | |
Schuette | weekly docetaxel | 3-weekly docetaxel | | | | - | |
Gervais | weekly docetaxel | 3-weekly docetaxel | | | | - | |
Lai | weekly docetaxel | 3-weekly docetaxel | | | | - | |
Chen | weekly docetaxel | 3-weekly docetaxel | | | | - | |
REVEL, 2014 NCT | ramucirumab + docetaxel | docetaxel alone | | | Low risk of bias | - | |
Esteban, 2003 | paclitaxel 80mg/m2 | m2docetaxel 36 mg/ | | | | - | |